REFERENCES
Abreu-Mota, T., Hagen, K. R., Cooper, K., Jahrling, P. B., Tan, G., Wirblich, C., . . . Schnell, M. J. (2018). Non-neutralizing antibodies elicited by recombinant lassa-rabies vaccine are critical for protection against lassa fever. Nature Communications, 9 (1), 4223-018-06741-w. doi:10.1038/s41467-018-06741-w [doi]
Albertini, A. A., Ruigrok, R. W., & Blondel, D. (2011). Rabies virus transcription and replication. Advances in Virus Research, 79 , 1-22. doi:10.1016/B978-0-12-387040-7.00001-9 [doi]
Amann, R., Rohde, J., Wulle, U., Conlee, D., Raue, R., Martinon, O., & Rziha, H. J. (2013). A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.Journal of Virology, 87 (3), 1618-1630. doi:10.1128/JVI.02470-12 [doi]
Armbruster, N., Jasny, E., & Petsch, B. (2019). Advances in RNA vaccines for preventive indications: A case study of A vaccine against rabies. Vaccines, 7 (4), 10.3390/vaccines7040132. doi:E132 [pii]
Banyard, A. C., Horton, D. L., Freuling, C., Muller, T., & Fooks, A. R. (2013). Control and prevention of canine rabies: The need for building laboratory-based surveillance capacity. Antiviral Research, 98 (3), 357-364. doi:10.1016/j.antiviral.2013.04.004 [doi]
Baumgarth, N., Herman, O. C., Jager, G. C., Brown, L. E., Herzenberg, L. A., & Chen, J. (2000). B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. The Journal of Experimental Medicine, 192 (2), 271-280. doi:10.1084/jem.192.2.271 [doi]
Boes, M., Esau, C., Fischer, M. B., Schmidt, T., Carroll, M., & Chen, J. (1998). Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. Journal of Immunology (Baltimore, Md.: 1950), 160 (10), 4776-4787.
Chen, T., Zhou, X., Qi, Y., Mi, L., Sun, X., Zhang, S., . . . Hu, R. (2019). Feline herpesvirus vectored-rabies vaccine in cats: A dual protection. Vaccine, 37 (16), 2224-2231. doi:S0264-410X(19)30310-X [pii]
Chulasugandha, P., Khawplod, P., Havanond, P., & Wilde, H. (2006). Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in thai children. Vaccine, 24 (9), 1478-1482. doi:S0264-410X(05)00993-X [pii]
Cliquet, F., & Picard-Meyer, E. (2004). Rabies and rabies-related viruses: A modern perspective on an ancient disease. Revue Scientifique Et Technique (International Office of Epizootics), 23 (2), 625-642. doi:10.20506/rst.23.2.1514 [doi]
Cobleigh, M. A., Bradfield, C., Liu, Y., Mehta, A., & Robek, M. D. (2012). The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate. Journal of Virology, 86 (8), 4253-4261. doi:10.1128/JVI.05991-11 [doi]
DeBuysscher, B. L., Scott, D., Marzi, A., Prescott, J., & Feldmann, H. (2014). Single-dose live-attenuated nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine, 32 (22), 2637-2644. doi:10.1016/j.vaccine.2014.02.087 [doi]
Diamond, M. S., Sitati, E. M., Friend, L. D., Higgs, S., Shrestha, B., & Engle, M. (2003). A critical role for induced IgM in the protection against west nile virus infection. The Journal of Experimental Medicine, 198 (12), 1853-1862. doi:10.1084/jem.20031223 [doi]
Dong, F., Li, D., Wen, D., Li, S., Zhao, C., Qi, Y., . . . Zheng, A. (2019). Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. NPJ Vaccines, 4 , 5-018-0096-y. eCollection 2019. doi:10.1038/s41541-018-0096-y [doi]
Dorfmeier, C. L., Lytle, A. G., Dunkel, A. L., Gatt, A., & McGettigan, J. P. (2012). Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection. Journal of Virology, 86 (21), 11533-11540. doi:10.1128/JVI.00615-12 [doi]
Dorfmeier, C. L., Shen, S., Tzvetkov, E. P., & McGettigan, J. P. (2013). Reinvestigating the role of IgM in rabies virus postexposure vaccination. Journal of Virology, 87 (16), 9217-9222. doi:10.1128/JVI.00995-13 [doi]
Ertl, H. C. J. (2019). New rabies vaccines for use in humans.Vaccines, 7 (2), 10.3390/vaccines7020054. doi:E54 [pii]
Flamand, A., Raux, H., Gaudin, Y., & Ruigrok, R. W. (1993). Mechanisms of rabies virus neutralization. Virology, 194 (1), 302-313. doi:S0042-6822(83)71261-4 [pii]
Fooks, A. R., Cliquet, F., Finke, S., Freuling, C., Hemachudha, T., Mani, R. S., . . . Banyard, A. C. (2017). Rabies. Nature Reviews.Disease Primers, 3 , 17091. doi:10.1038/nrdp.2017.91 [doi]
Fooks, A. R., Johnson, N., Brookes, S. M., Parsons, G., & McElhinney, L. M. (2003). Risk factors associated with travel to rabies endemic countries. Journal of Applied Microbiology, 94 Suppl , 31S-36S. doi:1883 [pii]
Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., . . . Global Alliance for Rabies Control Partners for Rabies Prevention. (2015). Estimating the global burden of endemic canine rabies. PLoS Neglected Tropical Diseases, 9 (4), e0003709. doi:10.1371/journal.pntd.0003709 [doi]
Hangartner, L., Zinkernagel, R. M., & Hengartner, H. (2006). Antiviral antibody responses: The two extremes of a wide spectrum. Nature Reviews.Immunology, 6 (3), 231-243. doi:nri1783 [pii]
Kamoltham, T., Khawplod, P., & Wilde, H. (2002). Rabies intradermal post-exposure vaccination of humans using reconstituted and stored vaccine. Vaccine, 20 (27-28), 3272-3276. doi:S0264410X02002992 [pii]
Kamoltham, T., Thinyounyong, W., Phongchamnaphai, P., Phraisuwan, P., Khawplod, P., Banzhoff, A., & Malerczyk, C. (2007). Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. The Journal of Pediatrics, 151 (2), 173-177. doi:S0022-3476(07)00170-9 [pii]
Kopf, M., Brombacher, F., & Bachmann, M. F. (2002). Role of IgM antibodies versus B cells in influenza virus-specific immunity.European Journal of Immunology, 32 (8), 2229-2236. doi:10.1002/1521-4141(200208)32:83.0.CO;2-T [doi]
Madhusudana, S. N., Subha, S., Thankappan, U., & Ashwin, Y. B. (2012). Evaluation of a direct rapid immunohistochemical test (dRIT) for rapid diagnosis of rabies in animals and humans. Virologica Sinica, 27 (5), 299-302. doi:10.1007/s12250-012-3265-6 [doi]
Marzi, A., Feldmann, F., Geisbert, T. W., Feldmann, H., & Safronetz, D. (2015). Vesicular stomatitis virus-based vaccines against lassa and ebola viruses. Emerging Infectious Diseases, 21 (2), 305-307. doi:10.3201/eid2102.141649 [doi]
Moore, S. M., & Hanlon, C. A. (2010). Rabies-specific antibodies: Measuring surrogates of protection against a fatal disease. PLoS Neglected Tropical Diseases, 4 (3), e595. doi:10.1371/journal.pntd.0000595 [doi]
Nandi, S., & Kumar, M. (2010). Development in immunoprophylaxis against rabies for animals and humans. Avicenna Journal of Medical Biotechnology, 2 (1), 3-21.
Park, J. E., Li, K., Barlan, A., Fehr, A. R., Perlman, S., McCray, P. B.,Jr, & Gallagher, T. (2016). Proteolytic processing of middle east respiratory syndrome coronavirus spikes expands virus tropism.Proceedings of the National Academy of Sciences of the United States of America, 113 (43), 12262-12267. doi:1608147113 [pii]
Racine, R., & Winslow, G. M. (2009). IgM in microbial infections: Taken for granted? Immunology Letters, 125 (2), 79-85. doi:10.1016/j.imlet.2009.06.003 [doi]
Ramya, R., Mohana Subramanian, B., Sivakumar, V., Senthilkumar, R. L., Sambasiva Rao, K. R., & Srinivasan, V. A. (2011). Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice.Clinical and Vaccine Immunology : CVI, 18 (10), 1673-1679. doi:10.1128/CVI.05258-11 [doi]
Rupprecht, C. E., Nagarajan, T., & Ertl, H. (2016). Current status and development of vaccines and other biologics for human rabies prevention.Expert Review of Vaccines, 15 (6), 731-749. doi:10.1586/14760584.2016.1140040 [doi]
Schnell, M. J., Johnson, J. E., Buonocore, L., & Rose, J. K. (1997). Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell, 90 (5), 849-857. doi:S0092-8674(00)80350-5 [pii]
Smith, J. S., Yager, P. A., & Baer, G. M. (1973). A rapid reproducible test for determining rabies neutralizing antibody. Bulletin of the World Health Organization, 48 (5), 535-541.
Tober, R., Banki, Z., Egerer, L., Muik, A., Behmuller, S., Kreppel, F., . . . Kimpel, J. (2014). VSV-GP: A potent viral vaccine vector that boosts the immune response upon repeated applications. Journal of Virology, 88 (9), 4897-4907. doi:10.1128/JVI.03276-13 [doi]
Wang, C., Dulal, P., Zhou, X., Xiang, Z., Goharriz, H., Banyard, A., . . . Douglas, A. D. (2018). A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. PLoS Neglected Tropical Diseases, 12 (10), e0006870. doi:10.1371/journal.pntd.0006870 [doi]
Wang, X., Fang, Z., Xiong, J., Yang, K., Chi, Y., Tang, X., . . . Zhou, D. (2019). A chimpanzee adenoviral vector-based rabies vaccine protects beagle dogs from lethal rabies virus challenge. Virology, 536 , 32-38. doi:S0042-6822(19)30198-9 [pii]
Wu, F., Fan, X., Yue, Y., Xiong, S., & Dong, C. (2014). A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis. Vaccine, 32 (31), 3917-3926. doi:10.1016/j.vaccine.2014.05.052 [doi]
Zhu, S., & Guo, C. (2016). Rabies control and treatment: From prophylaxis to strategies with curative potential. Viruses, 8 (11), 10.3390/v8110279. doi:E279 [pii]
Zinkernagel, R. M., Adler, B., & Holland, J. J. (1978). Cell-mediated immunity to vesicular stomatitis virus infections in mice.Experimental Cell Biology, 46 (1-2), 53-70. doi:10.1159/000162882 [doi]